Business Context and Reporting Period
This Form 8-K Current Report was filed by Aerovate Therapeutics, Inc. (not Jade Biosciences, Inc.) on January 23, 2023, covering events occurring on January 19, 2023. The company is a Delaware corporation listed on the Nasdaq Global Market under the symbol AVTE and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Donald J. Santel as a member of the Board of Directors, effective January 19, 2023. Key details include:
- Mr. Santel serves as a Class I director until the 2025 annual meeting.
- He was determined to be independent under Nasdaq listing standards.
- He was appointed to the Nominating and Corporate Governance Committee, which now consists of Dr. Grayzel, Dr. Resnick, and Mr. Santel.
- The Compensation and Audit Committee compositions remain unchanged.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. Regarding compensation, Mr. Santel will receive an equity award and cash compensation for fiscal year 2023 in accordance with the Company's Non-Employee Director Compensation Policy. He has also entered into a standard indemnification agreement with the Company. No unusual items or contingencies were disclosed.
Investor Verification Checklist
- Verify the correct registrant name is Aerovate Therapeutics, Inc., not Jade Biosciences, Inc.
- Confirm the independence status of the new director, Donald J. Santel, per Nasdaq standards.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for the specific terms of the equity award and cash compensation granted to Mr. Santel.